首页> 外文期刊>Nature >IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
【24h】

IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics

机译:IDH1(R132H)突变增加了小鼠造血祖细胞并改变了表观遗传学

获取原文
获取原文并翻译 | 示例
       

摘要

Mutations in the IDH1 and IDH2 genes encoding isocitrate dehydrogenases are frequently found in human glioblastomas1 and cytogenetically normal acute myeloid leukaemias (AML)2. These alterations are gain-of-function mutations in that they drive the synthesis of the 'oncometabolite' R-2-hydroxyglutarate (2HG)3. It remains unclear how IDH1 and IDH2 mutations modify myeloid cell development and promote leukaemogenesis. Here we report the characterization of conditional knock-in (KI) mice in which the most common IDH1 mutation, IDH1(R132H), is inserted into the endogenous murine Idhl locus and is expressed in all haematopoietic cells (Vav-KI mice) or specifically in cells of the myeloid lineage (LysM-KI mice). These mutants show increased numbers of early haematopoietic progenitors and develop splenomegaly and anaemia with extramedullary haematopoiesis, suggesting a dysfunctional bone marrow niche. Furthermore, LysM-KI cells have hypermethylated histones and changes to DNA methyiation similar to those observed in human IDH1- or JDH2-mutant AML. To our knowledge, our study is the first to describe the generation and characterization of conditional IDH1(R132H)-KI mice, and also the first report to demonstrate the induction of a leukaemic DNA methyiation signature in a mouse model. Our report thus sheds light on the mechanistic links between IDH1 mutation and human AML.
机译:编码异柠檬酸脱氢酶的IDH1和IDH2基因突变经常在人胶质母细胞瘤1和细胞遗传学正常的急性髓细胞白血病(AML)2中发现。这些改变是功能获得性突变,因为它们驱动“竞争性代谢物” R-2-羟基戊二酸酯(2HG)3的合成。尚不清楚IDH1和IDH2突变如何修饰髓样细胞发育并促进白细胞生成。在这里,我们报告条件性敲入(KI)小鼠的特征,其中最常见的IDH1突变IDH1(R132H)被插入内源性鼠Idhl基因座,并在所有造血细胞(Vav-KI小鼠)中表达在髓系谱系(LysM-KI小鼠)的细胞中。这些突变体显示出早期造血祖细胞数量增加,并发展为脾肿大和贫血,并伴有髓外造血功能,提示骨髓小生境功能异常。此外,LysM-KI细胞具有高甲基化的组蛋白和类似于人类IDH1或JDH2突变AML中观察到的DNA甲基化变化。据我们所知,我们的研究是第一个描述条件IDH1(R132H)-KI小鼠的产生和特征的研究,也是第一个证明在小鼠模型中诱导白血病DNA甲基化标记的报告。因此,我们的报告阐明了IDH1突变与人类AML之间的机制联系。

著录项

  • 来源
    《Nature》 |2012年第7413期|p.656-659|共4页
  • 作者单位

    The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute, University Health Network, Toronto, Ontario M5G 2C1, Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada,Department of Neuropathology,Heinrich Heine University,40225 Dcisseldorf,Germany;

    School of Medicine and Dentistry,University of Rochester,Rochester,New York 14642,USA;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada,Department of Medical Biophysics,University of Toronto,Toronto,Ontario M5G 2C1,Canada;

    Department of Immunology,Sunnybrook Research Institute,University of Toronto,Toronto,Ontario M4N 3M5,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    Agios Pharmaceuticals Incorporated,Cambridge,Massachusetts 02139,USA;

    Agios Pharmaceuticals Incorporated,Cambridge,Massachusetts 02139,USA;

    University Health Network Microarray Center,Toronto,Ontario M5S1A8,Canada;

    Department of Neuropathology,Heinrich Heine University,40225 Dcisseldorf,Germany;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada;

    Department of Medical Biophysics,University of Toronto,Toronto,Ontario M5G 2C1,Canada;

    Department of Pathology,University of Michigan,Ann Arbor,Michigan 48109,USA;

    Weill Cornell Medical College,Cornell University,New York,New York 10021,USA;

    Department of Immunology,Sunnybrook Research Institute,University of Toronto,Toronto,Ontario M4N 3M5,Canada;

    The Campbell Family Institute for Breast Cancer Research,Ontario Cancer Institute,University Health Network,Toronto,Ontario M5G 2C1,Canada,Department of Medical Biophysics,University of Toronto,Toronto,Ontario M5G 2C1,Canada;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:13

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号